Efavirenz

Generic Name
Efavirenz
Brand Names
Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
Drug Type
Small Molecule
Chemical Formula
C14H9ClF3NO2
CAS Number
154598-52-4
Unique Ingredient Identifier
JE6H2O27P8
Background

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication

For use in combination treatment of HIV infection (AIDS)

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Glaxo Wellcome
Target Recruit Count
80
Registration Number
NCT00002213
Locations
🇺🇸

Niaid / Nih, Bethesda, Maryland, United States

🇺🇸

Northwestern Univ Med School AIDS Treatment Unit, Chicago, Illinois, United States

🇺🇸

Univ Int Med Assoc Inc / Holmes Hosp / U of Cincinnati, Cincinnati, Ohio, United States

and more 6 locations

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

Phase 4
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Glaxo Wellcome
Target Recruit Count
150
Registration Number
NCT00005018
Locations
🇺🇸

East Bay AIDS Ctr, Berkeley, California, United States

🇺🇸

Altamed Medical Health Services, Los Angeles, California, United States

🇺🇸

Gary Richmond MD, Fort Lauderdale, Florida, United States

and more 20 locations

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Phase 4
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Agouron Pharmaceuticals
Target Recruit Count
200
Registration Number
NCT00005000
Locations
🇺🇸

Agouron Pharmaceuticals Inc, San Diego, California, United States

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
80
Registration Number
NCT00002387
Locations
🇺🇸

San Francisco Gen Hosp, San Francisco, California, United States

🇺🇸

Brown Univ / Miriam Hosp, Providence, Rhode Island, United States

🇺🇸

Rush Med Ctr / Section of Infectious Diseases, Chicago, Illinois, United States

and more 5 locations

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Glaxo Wellcome
Registration Number
NCT00004852
Locations
🇺🇸

Univ of Texas / Med School at Houston, Houston, Texas, United States

🇺🇸

Harbor - UCLA Med Ctr, Torrance, California, United States

🇺🇸

Bach and Godofsky, Bradenton, Florida, United States

and more 59 locations

A Study of Indinavir Taken With or Without DMP 266

Phase 3
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Dupont Merck
Target Recruit Count
300
Registration Number
NCT00002393
Locations
🇺🇸

Tulane Univ / Tulane / LSU Clinical Trials Unit, New Orleans, Louisiana, United States

🇺🇸

Vanderbilt Univ, Nashville, Tennessee, United States

🇺🇸

Chicago Ctr for Clinical Research, Chicago, Illinois, United States

and more 9 locations

A Study to Compare Two Anti-HIV Drug Combinations

Phase 3
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
146
Registration Number
NCT00002447
Locations
🇺🇸

UCSF - San Francisco Gen Hosp, San Francisco, California, United States

🇺🇸

Saint Michael's Med Ctr / Dept of Infectious Diseases, Newark, New Jersey, United States

🇺🇸

Associates in Research, Fort Myers, Florida, United States

and more 23 locations

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2012-06-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
900
Registration Number
NCT00000919
Locations
🇺🇸

Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States

🇺🇸

Marin County Specialty Clinic, San Rafael, California, United States

🇺🇸

Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States

and more 77 locations

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

First Posted Date
2001-08-31
Last Posted Date
2006-03-14
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
56
Registration Number
NCT00017758
Locations
🇺🇸

Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States

🇺🇸

Univ of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Washington Univ School of Medicine, St Louis, Missouri, United States

and more 7 locations

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-11-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
68
Registration Number
NCT00002239
Locations
🇺🇸

UCLA Care Ctr, Los Angeles, California, United States

🇺🇸

AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

🇺🇸

Pennsylvania Oncology and Hematology Associates, Philadelphia, Pennsylvania, United States

and more 16 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy